Frontier Biotechnologies Inc.

New

Frontier Biotechnologies Inc. is a research-based pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing significant unmet medical needs. - Its lead product candidate ALBUVIRTIDE, a novel long-acting anti-HIV agent. - The second lead drug candidate AB001 is a third generation topical patch for the management of pain and inflammation, and a phase 2 clinical trial of AB001 for the treatment of chronic low back pain was successfully completed in the US. - Frontier Biotechnologies, Inc., announced it has signed an agreement with The Rockefeller University of the US for the worldwide license for combining 3BNC117, a novel broad-spectrum HIV neutralizing antibody, with ALBUVIRTIDE for the treatment and prophylaxis of HIV infection and AIDS.

Location: 
Sub-event: BIO18

Contact details

Hi-Tech Park, Jiangning District
100010
Nanjing
China